Drug and biotech com­pa­nies join lob­by­ing push on Chi­na bill as scruti­ny of WuXi con­tin­ues

Al­most 20 bio­phar­ma and life sci­ences com­pa­nies have reg­is­tered to lob­by on a bill that could ban US com­pa­nies from work­ing with Chi­nese life sci­ences con­trac­tors, ac­cord­ing to fed­er­al records.

Since the Biose­cure Act was in­tro­duced in Jan­u­ary, most health­care com­pa­nies have steered away from pub­licly com­ment­ing on it. But as the pro­pos­al slow­ly ad­vances in Con­gress — and as the con­se­quences of a ban on WuXi Apptec, WuXi Bi­o­log­ics and ge­nomics com­pa­nies like BGI have come in­to fo­cus — com­pa­nies in re­cent months launched lob­by­ing ef­forts on the bill.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.